Clinical remission · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in clinical remission compared with placebo or Control (low certainty).
1 finding from 1 review
CDAI <150 at 24 weeks · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes CDAI <150 at 24 weeks compared with placebo or Control (very low certainty).
1 finding from 1 review
Fistula Closure short‐term · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell may leads to higher fistula Closure short‐term compared with placebo or Control (low certainty).
1 finding from 1 review
Fistula closure in long‐term · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell may leads to higher fistula closure in long‐term compared with placebo or Control (low certainty).
1 finding from 1 review
Total adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes total Adverse Events compared with placebo or Control (very low certainty).
1 finding from 1 review
Serious adverse events · Induction of Remission in Medically Refractory Crohn's Disease
Summary of findings table ‐ Stem Cell showed no clear difference in serious Adverse Events compared with placebo or Control (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Induction of Remission in Medically Refractory Crohn's Disease
It is very uncertain whether summary of findings table ‐ Stem Cell changes withdrawal due to adverse events compared with placebo or Control (very low certainty).
1 finding from 1 review
Seizure frequency · people with ADHD and epilepsy
1 finding from 1 review
Proportion of individuals withdrawing from treatment · people with ADHD and epilepsy
Osmotic‐release oral system methylphenidate probably leads to higher proportion of people withdrawing from treatment compared with placebo (moderate certainty).
1 finding from 1 review
Seizure severity · people with ADHD and epilepsy
1 finding from 1 review
50% or greater reduction in seizure frequency · people with ADHD and epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ADHD symptoms · people with ADHD and epilepsy
1 finding from 1 review
Adverse drug events · people with ADHD and epilepsy
1 finding from 1 review
Number of participants with any serious adverse events · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of adverse events requiring discontinuation of treatment ‐ not reported · primary progressive multiple sclerosis
Ocrelizumab showed no clear difference in number of participants experiencing treatment discontinuation caused… compared with placebo (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · primary progressive multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing disability progression · primary progressive multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing disability progression compared with placebo (low certainty).
1 finding from 1 review
Number of participants with any adverse events · primary progressive multiple sclerosis
Ocrelizumab probably leads to higher number of participants with any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Exacerbation frequency · people with bronchiectasis
14 days on/off antibiotic regimen probably leads to lower exacerbation frequency compared with 14 days on/off placebo regimen (moderate certainty).
2 findings from 1 review
RR 0.75 [0.61, 0.93]
Studies not reported
Moderate
no estimate extracted
Studies not reported
Moderate